Breaking News

Ray Therapeutics, Forge Biologics Enter Gene Therapy Mfg. Pact

Forge will provide adeno-associated viral process development, scale-up engineering and cGMP manufacturing services for Ray’s program, Ray-001.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Ray Therapeutics, a biotechnology company developing optogenetic gene therapies for retinal degenerative conditions, and Forge Biologics, a gene therapy-focused contract development and manufacturing organization, entered a manufacturing partnership to advance Ray Therapeutics’ lead optogenetics gene therapy program, Ray-001, into clinical trials for patients with retinitis pigmentosa.   Forge will provide adeno-associated viral (AAV) process development, scale-up engineering and cGMP manu...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters